Hongyan Liu

发表

CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models

Junnian Zheng, Huizhong Li, Gang Wang, 2019, Journal of immunotherapy.

Bortezomib improves adoptive carbonic anhydrase IX‑specific chimeric antigen receptor‑modified NK92 cell therapy in mouse models of human renal cell carcinoma.

Junnian Zheng, Huizhong Li, Qing Zhang, 2018, Oncology reports.

Akt inhibition at the initial stage of CAR-T preparation enhances the CAR-positive expression rate, memory phenotype and in vivo efficacy.

Junnian Zheng, Qing Zhang, Q. Fu, 2019, American journal of cancer research.

Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds

S. Sidhu, A. Saxena, Donghui Wu, 2017, Front. Immunol..

Tyrosine Kinase Inhibitor Cabozantinib Inhibits Murine Renal Cancer by Activating Innate and Adaptive Immunity

Junnian Zheng, Gang Wang, Qing Zhang, 2021, Frontiers in Oncology.

Chimeric antigen receptor-T cell therapy for solid tumors require new clinical regimens

Junnian Zheng, Qing Zhang, Liantao Li, 2017, Expert review of anticancer therapy.

Lenvatinib promotes antitumor immunity by enhancing the tumor infiltration and activation of NK cells.

Junnian Zheng, Huizhong Li, Qing Zhang, 2019, American journal of cancer research.

Thrombin-activated platelet rich plasma (PRP) enhanced osteogenic differentiation of bone marrow mesenchymal stem cells by activing autophagy through miR-140-3p/SPRED2 axis

Hongyan Liu, B. Yan, Shuting Jiang, 2020 .

Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models

Junnian Zheng, Huizhong Li, Qing Zhang, 2018, Journal of immunology research.